Giros B, Gros C, Solhonne B, Schwartz J C
Mol Pharmacol. 1986 Mar;29(3):281-7.
In addition to "enkephalinase" (EC 3.4.24.11), two enkephalin-hydrolyzing aminopeptidases recently identified in cerebral membranes--aminopeptidase M (EC 3.4.11.2) and a "puromycin-sensitive" aminopeptidase (also designated "MII" or "aminoenkephalinase")--are potentially involved in endogenous enkephalin inactivation. Their participation in the hydrolysis of the endogenous (Met5)enkephalin released by depolarization of slices from rat globus pallidus was assessed, using three inhibitory agents: bestatin, puromycin, and anti-aminopeptidase M antibodies. The selectivity and potency of these agents were first determined by evaluating their IC50 values for inhibition of 3Henkephalin hydrolysis by increasingly complex preparations comprising semipurified aminopeptidases, pallidal membranes, and pallidal slices. Bestatin was a fairly potent inhibitor but lacked selectivity, as there was only a 3-fold difference between its IC50 values for the two aminopeptidases, and it displayed restricted diffusion and degradation in the slice preparation. Puromycin discriminated well between the two aminopeptidases (30-fold difference in IC50 values) and did not show any apparent restricted diffusion in the slice preparation. Antiaminopeptidase M antibodies were highly discriminant (greater than 300-fold difference in IC50 values for the two aminopeptidases) but displayed restricted diffusion. Analysis of the concentration-protection curves of the three agents for recovery of the (Met5)enkephalin released from pallidal slices in the presence of the "enkephalinase" inhibitor, thiorphan, indicated that both aminopeptidases participated in enkephalin degradation but that the role of aminopeptidase M was largely predominant, in contrast with its low relative activity in the preparation.
除了“脑啡肽酶”(EC 3.4.24.11)外,最近在脑膜中鉴定出的两种脑啡肽水解氨基肽酶——氨基肽酶M(EC 3.4.11.2)和一种“嘌呤霉素敏感”氨基肽酶(也称为“MII”或“氨基脑啡肽酶”)——可能参与内源性脑啡肽的失活。使用三种抑制剂:贝司他汀、嘌呤霉素和抗氨基肽酶M抗体,评估了它们在大鼠苍白球切片去极化释放的内源性(Met5)脑啡肽水解中的参与情况。这些试剂的选择性和效力首先通过评估它们对由半纯化氨基肽酶、苍白球膜和苍白球切片组成的日益复杂的制剂抑制[3H](Met5)脑啡肽水解的IC50值来确定。贝司他汀是一种相当有效的抑制剂,但缺乏选择性,因为它对两种氨基肽酶的IC50值之间只有3倍的差异,并且在切片制剂中显示出有限的扩散和降解。嘌呤霉素对两种氨基肽酶有很好的区分(IC50值相差30倍),并且在切片制剂中没有显示出任何明显的扩散受限。抗氨基肽酶M抗体具有高度的区分性(两种氨基肽酶的IC50值相差大于300倍),但显示出扩散受限。在“脑啡肽酶”抑制剂硫磷酰胺存在的情况下,分析这三种试剂对从苍白球切片释放的(Met5)脑啡肽恢复的浓度-保护曲线表明,两种氨基肽酶都参与了脑啡肽的降解,但氨基肽酶M的作用在很大程度上占主导地位,这与其在制剂中的相对低活性形成对比。